Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39596460

Authors

Ioanna Aggeletopoulou

Christos Triantos

Affiliations

Soon will be listed here.

Abstract

Irritable bowel syndrome (IBS) is one of the most prevalent functional gastrointestinal disorders characterized by recurrent abdominal pain and altered bowel habits. The exact pathophysiological mechanisms for IBS development are not completely understood. Several factors, including genetic predisposition, environmental and psychological influences, low-grade inflammation, alterations in gastrointestinal motility, and dietary habits, have been implicated in the pathophysiology of the disorder. Additionally, emerging evidence highlights the role of gut microbiota in the pathophysiology of IBS. This review aims to thoroughly investigate how alterations in the gut microbiota impact physiological functions such as the brain-gut axis, immune system activation, mucosal inflammation, gut permeability, and intestinal motility. Our research focuses on the dynamic "microbiome shifts", emphasizing the enrichment or depletion of specific bacterial taxa in IBS and their profound impact on disease progression and pathology. The data indicated that specific bacterial populations are implicated in IBS, including reductions in beneficial species such as and , along with increases in potentially harmful bacteria like Firmicutes and Proteobacteria. Emphasis is placed on the imperative need for further research to delineate the role of specific microbiome alterations and their potential as therapeutic targets, providing new insights into personalized treatments for IBS.

References

Liu H, Wu H, Chen Y, Chen Y, Shen X, Liu T . Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017; 49(4):331-337. DOI: 10.1016/j.dld.2017.01.142. View

Lee K, Kim Y, Kim J, Kwon H, Kim D, Cho S . The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2009; 23(11):1689-94. DOI: 10.1111/j.1440-1746.2008.05574.x. View

Flacco M, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F . Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019; 23(7):2986-3000. DOI: 10.26355/eurrev_201904_17580. View

Lee J, Kim S, Chun Y, Chun Y, Shin S, Choi C . Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using H-NMR coupled with multivariate statistical analysis. Neurogastroenterol Motil. 2020; 32(6):e13830. DOI: 10.1111/nmo.13830. View

Meydan C, Afshinnekoo E, Rickard N, Daniels G, Kunces L, Hardy T . Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions. Precis Clin Med. 2020; 3(2):136-146. PMC: 7327130. DOI: 10.1093/pcmedi/pbaa013. View

Duan R, Zhu S, Wang B, Duan L . Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review. Clin Transl Gastroenterol. 2019; 10(2):e00012. PMC: 6407812. DOI: 10.14309/ctg.0000000000000012. View

Canakis A, Haroon M, Weber H . Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2019; 27(1):28-35. DOI: 10.1097/MED.0000000000000523. View

Geng S, Yang L, Cheng F, Zhang Z, Li J, Liu W . Gut Microbiota Are Associated With Psychological Stress-Induced Defections in Intestinal and Blood-Brain Barriers. Front Microbiol. 2020; 10:3067. PMC: 6974438. DOI: 10.3389/fmicb.2019.03067. View

Dudzinska E, Grabrucker A, Kwiatkowski P, Sitarz R, Sienkiewicz M . The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome-Plant Metabolites in IBS Treatment. Pharmaceuticals (Basel). 2023; 16(10). PMC: 10609912. DOI: 10.3390/ph16101405. View

10.

Jeffery I, Das A, OHerlihy E, Coughlan S, Cisek K, Moore M . Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology. 2019; 158(4):1016-1028.e8. DOI: 10.1053/j.gastro.2019.11.301. View

11.

Ghoshal U, Shukla R, Srivastava D, Ghoshal U . Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in , Which Is Associated with Higher Methane Production. Gut Liver. 2016; 10(6):932-938. PMC: 5087933. DOI: 10.5009/gnl15588. View

12.

Pittayanon R, Lau J, Yuan Y, Leontiadis G, Tse F, Surette M . Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019; 157(1):97-108. DOI: 10.1053/j.gastro.2019.03.049. View

13.

Holtmann G, Ford A, Talley N . Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 1(2):133-146. DOI: 10.1016/S2468-1253(16)30023-1. View

14.

Toor D, Wsson M, Kumar P, Karthikeyan G, Kaushik N, Goel C . Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases. Int J Mol Sci. 2019; 20(10). PMC: 6567003. DOI: 10.3390/ijms20102432. View

15.

Mamieva Z, Poluektova E, Svistushkin V, Sobolev V, Shifrin O, Guarner F . Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?. World J Gastroenterol. 2022; 28(12):1204-1219. PMC: 8968486. DOI: 10.3748/wjg.v28.i12.1204. View

16.

Jadhav V, Han J, Fasina Y, Harrison S . Connecting gut microbiomes and short chain fatty acids with the serotonergic system and behavior in and other avian species. Front Physiol. 2022; 13:1035538. PMC: 9667555. DOI: 10.3389/fphys.2022.1035538. View

17.

Zheng D, Liwinski T, Elinav E . Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6):492-506. PMC: 7264227. DOI: 10.1038/s41422-020-0332-7. View

18.

Lach G, Schellekens H, Dinan T, Cryan J . Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. Neurotherapeutics. 2017; 15(1):36-59. PMC: 5794698. DOI: 10.1007/s13311-017-0585-0. View

19.

Bennet S, Keshteli A, Bercik P, Madsen K, Reed D, Vanner S . Application of metabolomics to the study of irritable bowel syndrome. Neurogastroenterol Motil. 2020; 32(6):e13884. DOI: 10.1111/nmo.13884. View

20.

Crouzet L, Gaultier E, Delhomme C, Cartier C, Delmas E, Dapoigny M . The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil. 2013; 25(4):e272-82. DOI: 10.1111/nmo.12103. View